Germinal neomutation of p53 gene in a patient presenting Li-Fraumeni syndrome and pancreatic adenocarcinoma [2];Néomutation germinale du gène p53 chez une malade présentant un syndrome de Li-Fraumeni et un adénocarcinome du pancréas

Gastroenterologie Clinique et Biologique

Volumn 30, Issue 3, 2006, Pages 484-486

  Lefrou, Laurent ^a   Godart, Bruno ^a   De Muret, Anne ^a   Scotto, Béatrice ^a   Dorval, Etienne ^a  

^a SERVICE DE DERMATOLOGIE   (France)

Author keywords

[No Author keywords available]

Indexed keywords

PROTEIN P53;

ADULT; ASCITES; CASE REPORT; CLINICAL FEATURE; COMPUTER ASSISTED TOMOGRAPHY; FAMILIAL CANCER; GENE MUTATION; GENETIC DISORDER; GERM LINE; HOSPITAL ADMISSION; HUMAN; LETTER; P53 GENE; PANCREAS ADENOCARCINOMA; TUMOR SUPPRESSOR GENE;

EID: 33745802010     PISSN: 03998320     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0399-8320(06)73212-2     Document Type: Letter

References (15)

1. Knudson AG. Antioncogenes and human cancer. Proc Natl Acad Sci USA 1993;90:10914-21.
2. Li FP, Fraumeni JF, Jr., Mulvihill JJ, Blattner WA, Dreyfus MG, Tucker MA, et al. A cancer family syndrome in twenty-four kindreds. Cancer Res 1988;48:5358-62.
3. Birch JM, Hartley AL, Tricker KJ, Prosser J, Condie A, Kelsey AM, et al. Prevalence and diversity of constitutional mutations in the p53 gene among 21 Li-Fraumeni families. Cancer Res 1994;54:1298-304.
4. Chompret A. The Li-Fraumeni syndrome. Biochimie 2002;84:75-82.
5. Varley JM. Germline TP53 mutations and Li-Fraumeni syndrome. Hum Mutat 2003;21:313-20.
6. Olivier M, Goldgar DE, Sodha N, Ohgaki H, Kleihues P, Hainaut P, et al. Li-Fraumeni and related syndromes: correlation between tumor type, family structure, and TP53 genotype. Cancer Res 2003;63:6643-50.
7. Cho Y, Gorina S, Jeffrey PD, Pavletich NP. Crystal structure of a p53 tumor suppressor-DNA complex: understanding tumorigenic mutations. Science 1994;265:346-55.
8. Birch JM, Blair V, Kelsey AM, Evans DG, Harris M, Tricker KJ, et al. Cancer phenotype correlates with constitutional TP53 genotype in families with the Li-Fraumeni syndrome. Oncogene 1998;17:1061-8.
9. Vahteristo P, Tamminen A, Karvinen P, Eerola H, Eklund C, Aaltonen LA, et al. p53, CHK2, and CHK1 genes in Finnish families with Li-Fraumeni syndrome: further evidence of CHK2 in inherited cancer predisposition. Cancer Res 2001;61:5718-22.
10. Evans SC, Lozano G. The Li-Fraumeni syndrome: an inherited susceptibility to cancer. Mol Med Today 1997;3:390-5.
11. Hisada M, Garber JE, Fung CY, Fraumeni JF, Jr., Li FP. Multiple primary cancers in families with Li-Fraumeni syndrome. J Natl Cancer Inst 1998;90:606-11.
12. Cowgill SM, Muscarella P. The genetics of pancreatic cancer. Am J Surg 2003;186:279-86.
13. Birch JM, Alston RD, McNally RJ, Evans DG, Kelsey AM, Harris M, et al. Relative frequency and morphology of cancers in carriers of germline TP53 mutations. Oncogene 2001;20:4621-8.
14. Soussi T, Dehouche K, Beroud C. p53 website and analysis of p53 gene mutations in human cancer: forging a link between epidemiology and carcinogenesis. Hum Mutat 2000;15:105-13.
15. Sener SF, Fremgen A, Menck HR, Winchester DP. Pancreatic cancer: a report of treatment and survival trends for 100,313 patients diagnosed from 1985-1995, using the National Cancer Database. J Am Coll Surg 1999;189:1-7.